AN2 Therapeutics (ANTX) Interest Expenses (2021 - 2026)
AN2 Therapeutics (ANTX) posted quarterly Interest Expenses of $7.3 million for Q1 2026, up 1384.99% year-over-year from $493000.0 in Q1 2025, and up 182925.0% quarter-over-quarter from $4000.0 in Q4 2025.
AN2 Therapeutics (ANTX) Interest Expenses (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Interest Expenses for 6 consecutive years, with $7.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses rose 1384.99% year-over-year to $7.3 million; the TTM figure through Mar 2026 stood at $7.3 million (up 1384.99% YoY), while the FY2025 annual figure was $170000.0, down 99.71% from the prior year.
- Interest Expenses rose to $7.3 million in Q1 2026 per ANTX's latest filing, from $4000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $41.8 million in Q4 2023 and bottomed at $4000.0 in Q4 2025.
- Historically, Interest Expenses has averaged $7.2 million across 5 years, with a median of $1.0 million in 2024.
- Annual changes were most pronounced in 2023 — Interest Expenses jumped 208990.0% — and 2024, when it slumped 99.21%.
- AN2 Therapeutics' Interest Expenses stood at $20000.0 in 2022, then surged by 208990.0% to $41.8 million in 2023, then plunged by 99.21% to $330000.0 in 2024, then plunged by 98.79% to $4000.0 in 2025, then surged by 182925.0% to $7.3 million in 2026.
- Business Quant data shows ANTX's Interest Expenses at $7.3 million in Q1 2026, $4000.0 in Q4 2025, and $372000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | AN2 Therapeutics | 226.04 Mn | 226.04 Mn | - | 12.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.68 Mn |
| Jun 30, 2026 | 12.68 Mn |
| Mar 31, 2026 | 7.32 Mn |
| Mar 31, 2026 | 7.32 Mn |
| Dec 31, 2025 | 4,000.00 |
| Dec 31, 2025 | 4,000.00 |
| Sep 30, 2025 | 372,000.00 |
| Sep 30, 2025 | 372,000.00 |
| Jun 30, 2025 | 133,000.00 |
| Jun 30, 2025 | 133,000.00 |
| Mar 31, 2025 | 493,000.00 |
| Mar 31, 2025 | 493,000.00 |
| Dec 31, 2024 | 330,000.00 |
| Dec 31, 2024 | 330,000.00 |
| Sep 30, 2024 | 176,000.00 |
| Sep 30, 2024 | 176,000.00 |
| Jun 30, 2024 | 549,000.00 |
| Jun 30, 2024 | 549,000.00 |
| Mar 31, 2024 | 1.00 Mn |
| Mar 31, 2024 | 1.00 Mn |